Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects
- PMID: 3987181
- DOI: 10.1038/clpt.1985.90
Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects
Abstract
3-OH-quinidine, a major quinidine metabolite, has been reported to have antiarrhythmic activity in animals and is suspected to contribute to the effect of quinidine in man. Four healthy subjects received 3-OH-quinidine in increasing oral doses (35, 100, 300 mg) to achieve serum concentrations in the range of those after quinidine dosing in patients. Blood and urine were collected up to 48 hours and blood pressure, heart rate, and averaged ECG complexes were recorded during 12 hours after dosing. Kinetic analysis revealed differences from published data for the parent drug. Renal clearance was 16 L/hr. The elimination t1/2 was 12.4 hours, substantially longer than that of quinidine. No systematic ECG changes were observed in two subjects with maximum concentrations of 55 and 215 micrograms/L. In the other two subjects who achieved higher maximum concentrations (447 and 918 micrograms/L), there was a significant relationship between the length of the corrected QT interval and the serum concentration of 3-OH-quinidine. These first dynamic results indicate that 3-OH-quinidine exerts effects in man resembling those of quinidine and may contribute to the antiarrhythmic activity of quinidine.
Similar articles
-
Kinetics and dynamics of quinidine-N-oxide in healthy subjects.Clin Pharmacol Ther. 1987 Sep;42(3):341-5. doi: 10.1038/clpt.1987.158. Clin Pharmacol Ther. 1987. PMID: 3621790
-
Pharmacokinetics and pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs.Eur J Drug Metab Pharmacokinet. 1984 Oct-Dec;9(4):315-24. doi: 10.1007/BF03189683. Eur J Drug Metab Pharmacokinet. 1984. PMID: 6532805
-
Clinical pharmacology of hydroxy-3(S)-dihydroquinidine in healthy volunteers following oral administration.J Cardiovasc Pharmacol. 1988 Oct;12(4):445-50. doi: 10.1097/00005344-198810000-00010. J Cardiovasc Pharmacol. 1988. PMID: 2465445 Clinical Trial.
-
Pharmacodynamics of 3-hydroxyquinidine alone and in combination with quinidine in healthy persons.Am J Cardiol. 1987 Mar 1;59(6):681-4. doi: 10.1016/0002-9149(87)91192-1. Am J Cardiol. 1987. PMID: 3825912 Clinical Trial.
-
Clinical pharmacokinetics of quinidine.Clin Pharmacokinet. 1980 Mar-Apr;5(2):150-68. doi: 10.2165/00003088-198005020-00003. Clin Pharmacokinet. 1980. PMID: 6988137 Review.
Cited by
-
Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.Br J Clin Pharmacol. 1990 Feb;29(2):248-53. doi: 10.1111/j.1365-2125.1990.tb03628.x. Br J Clin Pharmacol. 1990. PMID: 2306418 Free PMC article.
-
Therapeutic drug monitoring of antiarrhythmic drugs.Clin Pharmacokinet. 2003;42(7):647-63. doi: 10.2165/00003088-200342070-00004. Clin Pharmacokinet. 2003. PMID: 12844326 Review.
-
The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine.Br J Clin Pharmacol. 1988 Oct;26(4):415-21. doi: 10.1111/j.1365-2125.1988.tb03400.x. Br J Clin Pharmacol. 1988. PMID: 3190991 Free PMC article.
-
Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration.Eur J Drug Metab Pharmacokinet. 1986 Jul-Sep;11(3):233-8. doi: 10.1007/BF03189851. Eur J Drug Metab Pharmacokinet. 1986. PMID: 3816879 Clinical Trial.
-
Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.Drug Saf. 1990 Nov-Dec;5(6):393-420. doi: 10.2165/00002018-199005060-00002. Drug Saf. 1990. PMID: 2285495 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous